Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abstract 2939: CAVATAK-mediated oncolytic immunotherapy in advanced melanoma patients

(2015) Robert H. Andtbacka et al.   CANCER RESEARCH

In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy

(2014) Rebecca L. Read et al.   ANNALS OF SURGICAL ONCOLOGY

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

(2014) Miranda L. Broz et al.   CANCER CELL

Topical pharmacotherapy for skin cancer

(2014) Giuseppe Micali et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy

(2014) Christine E Engeland et al.   MOLECULAR THERAPY

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Trial Watch:

(2014) Jonathan Pol et al.   OncoImmunology

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

(2014) Howard L Kaufman et al.   Journal for ImmunoTherapy of Cancer

Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus

(2013) A. Kanerva et al.   CLINICAL CANCER RESEARCH

A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer

(2013) Kenneth H. Kim et al.   GYNECOLOGIC ONCOLOGY

Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans

(2013) Simona Bramante et al.   INTERNATIONAL JOURNAL OF CANCER

Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

(2013) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Intralesional immunotherapy for melanoma

(2013) Peter Hersey et al.   JOURNAL OF SURGICAL ONCOLOGY

Treatment of metastatic melanoma with electrochemotherapy

(2013) Luca G. Campana et al.   JOURNAL OF SURGICAL ONCOLOGY

Oncolytic Adenovirus With Temozolomide Induces Autophagy and Antitumor Immune Responses in Cancer Patients

(2013) Ilkka Liikanen et al.   MOLECULAR THERAPY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer

(2013) Paul Toomey et al.   PLoS One

Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination

(2012) Ahmad A. Tarhini et al.   JOURNAL OF IMMUNOTHERAPY

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease

(2009) T. R. Hercus et al.   BLOOD

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

(2008) Byeong-Ho Park et al.   LANCET ONCOLOGY